+

SK2762002A3 - Delayed-action form of administration containing tramadol saccharinate - Google Patents

Delayed-action form of administration containing tramadol saccharinate Download PDF

Info

Publication number
SK2762002A3
SK2762002A3 SK276-2002A SK2762002A SK2762002A3 SK 2762002 A3 SK2762002 A3 SK 2762002A3 SK 2762002 A SK2762002 A SK 2762002A SK 2762002 A3 SK2762002 A3 SK 2762002A3
Authority
SK
Slovakia
Prior art keywords
dosage forms
forms according
tramadol
coating
eudragit
Prior art date
Application number
SK276-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Johannes Bartholomaus
Heinrich Kugelmann
Iris Ziegler
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19940740A external-priority patent/DE19940740A1/de
Priority claimed from DE19940944A external-priority patent/DE19940944B4/de
Priority claimed from DE10023699A external-priority patent/DE10023699A1/de
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of SK2762002A3 publication Critical patent/SK2762002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fertilizers (AREA)
SK276-2002A 1999-08-31 2000-08-03 Delayed-action form of administration containing tramadol saccharinate SK2762002A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19940740A DE19940740A1 (de) 1999-08-31 1999-08-31 Pharmazeutische Salze
DE19940944A DE19940944B4 (de) 1999-08-31 1999-08-31 Retardierte, orale, pharmazeutische Darreichungsformen
DE10023699A DE10023699A1 (de) 1999-08-31 2000-05-16 Retardierte Darreichungsform enthaltend Tramadolsaccharinat
PCT/EP2000/007527 WO2001015683A1 (fr) 1999-08-31 2000-08-03 Forme d'administration a action retardee contenant du saccharinate de tramadol

Publications (1)

Publication Number Publication Date
SK2762002A3 true SK2762002A3 (en) 2002-07-02

Family

ID=27213855

Family Applications (2)

Application Number Title Priority Date Filing Date
SK276-2002A SK2762002A3 (en) 1999-08-31 2000-08-03 Delayed-action form of administration containing tramadol saccharinate
SK237-2002A SK2372002A3 (en) 1999-08-31 2000-08-29 Oral dosage forms

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK237-2002A SK2372002A3 (en) 1999-08-31 2000-08-29 Oral dosage forms

Country Status (21)

Country Link
US (2) US6576260B2 (fr)
EP (2) EP1207866B1 (fr)
JP (2) JP2003508430A (fr)
CN (2) CN1202815C (fr)
AT (1) ATE279186T1 (fr)
AU (2) AU781058B2 (fr)
BR (2) BR0013825A (fr)
CA (2) CA2388560A1 (fr)
CZ (2) CZ2002671A3 (fr)
ES (1) ES2226886T3 (fr)
HK (1) HK1047230B (fr)
HU (2) HUP0203623A2 (fr)
IL (2) IL148411A0 (fr)
MX (2) MXPA02002193A (fr)
NO (2) NO20020939L (fr)
NZ (2) NZ517559A (fr)
PL (2) PL354264A1 (fr)
PT (1) PT1207866E (fr)
SK (2) SK2762002A3 (fr)
UY (2) UY26321A1 (fr)
WO (2) WO2001015683A1 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2128883T3 (es) * 1996-04-26 1999-05-16 Jurgen Bauer Dispositivo de filtracion para la preparacion de una bebida.
SK2762002A3 (en) * 1999-08-31 2002-07-02 Gruenenthal Chemie Delayed-action form of administration containing tramadol saccharinate
DE19940740A1 (de) * 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
DE60107393T2 (de) 2000-03-01 2005-12-01 Euro-Celtique S.A. Verwendung von tramadol zur herstellung eines arzneimittels zur behandlung von funktionelle gastrointestinale krankenheiten
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
DE10108122A1 (de) * 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
JP4704685B2 (ja) * 2002-02-21 2011-06-15 バイオヴェイル ラボラトリーズ インターナショナル エスアールエル 徐放性製剤
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
DE10211289A1 (de) * 2002-03-14 2003-09-25 Basf Ag Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität
US20030175342A1 (en) * 2002-03-14 2003-09-18 Karl Kolter Coated pharmaceutical single-unit delayed-release forms, based on polyvinyl acetate
ES2314227T7 (es) * 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
ES2320438T7 (es) 2002-04-09 2013-02-14 Flamel Technologies Formulación farmaceútica oral de suspensión acuosa de microcápsulas que permiten la liberación modificada de principio(s) activo(s)
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
CN1662223A (zh) * 2002-06-27 2005-08-31 西拉格股份公司 含水溶性活性成分的球形微丸
SE0202353D0 (sv) * 2002-08-01 2002-08-01 Astrazeneca Ab New film coating
JP5189242B2 (ja) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20040266806A1 (en) 2003-04-08 2004-12-30 Sanghvi Suketu P. Pharmaceutical formulation
CN1812793A (zh) * 2003-06-27 2006-08-02 大塚制药株式会社 药物持续释放颗粒及其制备方法
US20040265372A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20040265373A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
DE102005024614A1 (de) * 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
KR101306635B1 (ko) 2005-06-27 2013-10-11 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온염의 개질-방출 제형
RU2008104638A (ru) 2005-07-07 2009-08-20 Фарнэм Компаниз, Инк. (Us) Фармацевтические композиции хорошо растворимых в воде лекарственных средств, обеспечивающих их замедленное высвобождение
PT2402005T (pt) 2005-08-24 2021-04-14 Endo Pharmaceuticals Inc Formulações de libertação sustentada de nalbufina
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
JP5269595B2 (ja) 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
US20070104788A1 (en) * 2005-11-10 2007-05-10 Seamus Mulligan Once-daily administration of central nervous system drugs
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
WO2007078895A2 (fr) * 2005-12-30 2007-07-12 Biovail Laboratories International S.R.L. Formulations de tramadol à libération modifiée et leurs utilisations
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
EP2137191B8 (fr) 2007-03-29 2016-06-08 Progenics Pharmaceuticals, Inc. Antagonistes de récepteurs opioïdes périphériques, et leurs utilisations
PL2565195T3 (pl) 2007-03-29 2015-10-30 Wyeth Llc Obwodowy receptor opioidowy i jego antagoniści oraz ich zastosowania
EP2022778A1 (fr) 2007-08-07 2009-02-11 Laboratorios del Dr. Esteve S.A. Forme cristalline du sel de (R,R)-tramadol-(S)-naproxène
CZ300468B6 (cs) * 2007-09-20 2009-05-27 Zentiva, A. S Léková forma obsahující tramadol s kontrolovaným uvolnováním po dobu 24 hodin a zpusob její prípravy
MX2010008138A (es) 2008-01-25 2010-08-10 Gruenenthal Gmbh Forma de dosis farmaceutica.
US20090246276A1 (en) * 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
JP4864024B2 (ja) * 2008-02-15 2012-01-25 エスエス製薬株式会社 時限放出製剤
KR101094231B1 (ko) * 2008-02-18 2011-12-14 하나제약 주식회사 서방성 고형 제제 및 그의 제조방법
US20110097395A1 (en) * 2008-03-08 2011-04-28 Najib Babul Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
PL2273983T3 (pl) 2008-05-09 2017-01-31 Grünenthal GmbH Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego
AU2009265034B2 (en) 2008-07-01 2015-09-03 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
EP2381937A2 (fr) 2008-12-31 2011-11-02 Upsher-Smith Laboratories, Inc. Compositions pharmaceutiques orales contenant un opioïde et procédés
NZ596667A (en) 2009-07-22 2013-09-27 Gruenenthal Chemie Hot-melt extruded controlled release dosage form
JP2012533586A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化安定化された不正使用防止剤形
CA2773521C (fr) 2009-09-17 2017-01-24 Upsher-Smith Laboratories, Inc. Produit a liberation prolongee comprenant une combinaison d'une amine non opioide et d'un medicament anti-inflammatoire non steroidal
WO2012003231A1 (fr) * 2010-06-30 2012-01-05 Upsher-Smith Laboratories, Inc. Compositions pharmaceutiques orales comprenant un composé contenant une amine et un sel d'un acide organique cyclique
EP2611425B1 (fr) 2010-09-02 2014-07-02 Grünenthal GmbH Forme pharmaceutique inviolable comportant un polymère anionique
WO2012028319A1 (fr) 2010-09-02 2012-03-08 Grünenthal GmbH Forme pharmaceutique inviolable comportant un sel inorganique
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
NO2736495T3 (fr) 2011-07-29 2018-01-20
CA2864949A1 (fr) 2012-02-28 2013-09-06 Grunenthal Gmbh Forme pharmaceutique inviolable comprenant un compose pharmacologiquement actif et un polymere anionique
EP2838512B1 (fr) 2012-04-18 2018-08-22 Grünenthal GmbH Forme pharmaceutique inviolable et résistante au basculement de dose
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
PL2872121T3 (pl) 2012-07-12 2019-02-28 SpecGx LLC Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2837391B1 (fr) * 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Succinate d'acétate d'hypromellose en tant que support d'extrusion à chaud, composition d'extrusion à chaud et procédé de production d'un extrudat thermofusible
CA3042642A1 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN103877057A (zh) * 2014-03-25 2014-06-25 王媛媛 一种盐酸美沙酮缓释片
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
MA40990A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
CA2998259A1 (fr) 2015-09-10 2017-03-16 Grunenthal Gmbh Protection contre un surdosage par voie orale a l'aide de formulations a liberation immediate dissuasives d'abus
AU2018360383A1 (en) 2017-11-02 2020-05-21 Natureceuticals Sdn. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
JP7378279B2 (ja) * 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362730A (en) * 1980-08-25 1982-12-07 Heinrich Mack Nachf. Chem-Pharm. Fabrik Vincamine saccharinate and a pharmaceutical composition containing it dissolved therein
DE3206725A1 (de) * 1981-05-13 1982-12-02 Merck Patent Gmbh, 6100 Darmstadt Schwer loesliche salze von aminoglykosidantibiotika
FR2576213B1 (fr) * 1985-01-21 1989-02-24 Cortial Nouveau procede d'obtention de formes pharmaceutiques a liberation prolongee
JP3079531B2 (ja) * 1988-12-27 2000-08-21 ポーラ化成工業株式会社 水中油型多相エマルション及びその製造法
JPH02282322A (ja) * 1989-01-31 1990-11-19 Ipa Internatl Pharma Agentur Gmbh 有効物質の浸食制御による放出システムおよびその製造方法
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
EP0811386B1 (fr) * 1996-05-07 2004-09-29 Pfizer Inc. Méthode de sélection d'un sel pour fabrication d'un complexe d'inclusion
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
DE59702733D1 (de) * 1996-08-15 2001-01-11 Losan Pharma Gmbh Gut schluckbare orale arzneiform
WO1999001111A1 (fr) * 1997-07-02 1999-01-14 Euro-Celtique, S.A. Formulations de tramadol stabilisees a liberation prolongee
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
DE19901692C2 (de) * 1999-01-18 2002-06-20 Gruenenthal Gmbh Verfahren zur Herstellung von Pellets mit einem Gehalt von bis zu 90 Gew.% eines pharmazeutischen Wirkstoffes
DE19901686A1 (de) * 1999-01-18 2000-07-20 Gruenenthal Gmbh Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung
DE19927688A1 (de) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
SK2762002A3 (en) * 1999-08-31 2002-07-02 Gruenenthal Chemie Delayed-action form of administration containing tramadol saccharinate

Also Published As

Publication number Publication date
CN1202815C (zh) 2005-05-25
EP1207866A1 (fr) 2002-05-29
HUP0203623A2 (hu) 2003-02-28
IL148422A0 (en) 2002-09-12
MXPA02002189A (es) 2002-09-30
IL148411A0 (en) 2002-09-12
HUP0203204A3 (en) 2004-06-28
UY26321A1 (es) 2000-10-31
MXPA02002193A (es) 2002-09-30
WO2001015683A1 (fr) 2001-03-08
US6576260B2 (en) 2003-06-10
PL354362A1 (en) 2004-01-12
NO20020975D0 (no) 2002-02-27
ATE279186T1 (de) 2004-10-15
JP2003511351A (ja) 2003-03-25
NO20020939L (no) 2002-04-22
CZ2002673A3 (cs) 2002-06-12
UY26318A1 (es) 2000-10-31
CN1384735A (zh) 2002-12-11
AU7511600A (en) 2001-03-26
PL354264A1 (en) 2003-12-29
CZ2002671A3 (cs) 2002-06-12
SK2372002A3 (en) 2002-08-06
NO20020975L (no) 2002-02-27
EP1207858A1 (fr) 2002-05-29
BR0013825A (pt) 2002-07-23
CA2391832C (fr) 2010-08-10
PT1207866E (pt) 2005-02-28
HUP0203204A2 (hu) 2003-01-28
AU781058B2 (en) 2005-05-05
WO2001015667A1 (fr) 2001-03-08
NZ517559A (en) 2004-08-27
CN1384740A (zh) 2002-12-11
NO20020939D0 (no) 2002-02-26
AU782943B2 (en) 2005-09-08
CA2391832A1 (fr) 2001-03-08
BR0013826A (pt) 2002-07-30
NZ517683A (en) 2003-08-29
CA2388560A1 (fr) 2001-03-08
US20030035835A1 (en) 2003-02-20
US20020176888A1 (en) 2002-11-28
JP2003508430A (ja) 2003-03-04
EP1207866B1 (fr) 2004-10-13
HK1047230B (zh) 2005-05-13
HK1047230A1 (en) 2003-02-14
ES2226886T3 (es) 2005-04-01
US7572463B2 (en) 2009-08-11
AU6279800A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
SK2762002A3 (en) Delayed-action form of administration containing tramadol saccharinate
US7906141B2 (en) Sustained-release, oral pharmaceutical forms of formulation
US6077533A (en) Powder-layered oral dosage forms
US5529790A (en) Delayed, sustained-release diltiazem pharmaceutical preparation
US6270805B1 (en) Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
EP0711152B1 (fr) Formes galeniques pour une administration orale, ayant une couche de poudre
US7611730B2 (en) Tramadol-based medicament
SK287574B6 (sk) Farmaceutická soľ farmaceuticky účinnej zlúčeniny a aspoň jednej náhrady cukru, liečivo, ktoré ju obsahuje, a jeho použitie
SK143794A3 (en) Preparation with gradual release containing a salt of morphine and method of its production
SK3722001A3 (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
RU2292877C2 (ru) Лекарственная ретард-форма, содержащая сахаринат трамадола
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载